-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The reason for the poor prognosis of pancreatic catheterized adenocarcinoma (PDAC) is that interstitrinal fibrosis is serious, and the multicellular micro-environment is complex, and the preclinical model is difficult to reproduce completely.
researchers aim to develop a complete, viable, three-dimensional multicellular structure and tissue-in vitro implant model that provides micro-environmental cues for the purpose of rapidly transforming treatments and providing information for individual medicine.
the researchers cut the PDAC tissue from the patient's surgical removal into 1-2mm implants and cultured it on gelatin sponges.
immune grouping showed that human PDAC implants survived for a total of 12 days and maintained their original tumor, substation and extracellular substation structure.
as a principle argument, they treated PDAC implants with Abraxane, one of the chemotherapy drugs currently used in PDAC17 first-line therapy, and added them to the medium every 3 days. Abraxane, which is 0.3 μg/mL or 4.2 μg/mL, fixed the exosome on the 12th day, then tunEL staining was performed to assess cell death and to observe the different degrees of response of the implants from different patient sources.
same time, they trans-dyed PDAC implants using polymer nanoparticles and Cy5 siRNA, and found that Cy5 siRNA had a large cytostypolyte distribution throughout the PDAC explant.
the use of QuPath for TUNEL (apoptosis test reagent) positive cells in implant culture showed an increase in cell death in the exosome treated by Abraxane compared to the untreated control group.
The team's model retains the 3D structure of human PDAC and offers many advantages over standard organoids, indicating that this approach has great potential to test the effects of different drugs on cancer and to provide personalized medications for subsequent patients, providing unprecedented opportunities for studying PDAC biology (including tumor-interstational interactions) and rapidly evaluating treatment responses to drive personalized treatment.
team members say they also need to address one of the limitations of the model -- they only looked at tumors in patients who had surgery, which accounted for only about 15 to 20 percent of pancreatic cancer patients, since the vast majority of patients had tumors that could not be surgically removed.
they also wanted to get tumor samples from patients with metastatic diseases to help all pancreatic cancer patients.